

**Title: Gastrointestinal involvement attenuates COVID-19 severity and mortality**

**Supplementary Materials**

Fig. S1. Sample allocation for different assays in COVID-19 patients and controls.

Fig. S2. Representative H&E staining of small intestinal biopsies of COVID-19 patients.

Fig. S3. Representative IF of small intestinal biopsies of COVID-19 patients.

Fig. S4. Representative IF of small intestinal biopsies of control patients.

Fig. S5. Altered immune populations in the lamina propria of COVID-19 patients compared to controls.

Fig. S6. Altered immune populations in the epithelial compartment (EC) of COVID-19 patients compared to controls.

Fig. S7. Altered immune populations in the blood of COVID-19 patients compared to controls.

Fig. S8. Altered T cell populations in blood and intestinal biopsies of COVID-19 patients compared to controls based on manual gating of the populations.

Fig. S9. Distinct expression profiles in the intestinal epithelial compartment (EC) and lamina propria (LP).

Fig. S10. Immune signature in the epithelial fraction of COVID-19 patients.

Fig. S11. Flow diagram of the Discovery Cohort.

Fig. S12. GI symptoms associated with reduced mortality and severity.

Fig. S13. COVID-19 patients with GI symptoms have reduced levels of circulating IL-6 and IL-8.

Fig. S14. Correlation matrix (Pearson's) for 92 markers contained in the Olink platform.

Table S1. Clinical characteristics of SARS-CoV-2 uninfected control patients who underwent endoscopic biopsies of the GI tract.

Table S2. Criteria for scoring disease severity in COVID-19 patients.

Table S3. Clinical characteristics of COVID-19 patients including their symptoms on presentation, co-morbidities and treatment regimens.

Table S4. Histopathological characteristics of COVID-19 patients.

Table S5. Histopathological characteristics of pre-pandemic controls.

Table S6. Discovery Cohort basic demographics, clinical characteristics and outcomes.

Table S7. COVID-19 disease severity and mortality in patients with and without GI symptoms in the Discovery Cohort.

Table S8. Basic demographics in survivors and non-survivors in the Discovery Cohort.

Table S9. Confidence intervals of odds ratio based on 1000 bootstrap iterations for severity, mortality and ICU admission in the Discovery Cohort.

Table S10. Age, gender and mortality in an External Validation (Italian) Cohort stratified by presence or absence of diarrhea on admission.


Table S11. Confidence interval of AUC (95%) based on 1000 bootstrap iterations for severity, mortality and ICU admission in the Internal Validation Cohort.

Table S12. IL-6, IL-8, TNF- $\alpha$ , and IL-1 $\beta$  concentrations on admission in patients with and without GI symptoms.

Table S13. Cluster assignment for each of the 92 Olink analytes.


Table S14. Olink analytes in patients with and without GI symptoms.

Table S15. List of antibodies used for microscopy studies.




Assays	Sample	COVID-19 cases	Controls
Mass Cytometry	Biopsy	13	9
	Blood	10	9
RNA Sequencing	Biopsy	13	8
	Blood	N/A	N/A

**Fig. S1 Sample allocation for different assays in COVID-19 patients and controls.** Venn diagrams showing blood and biopsy samples used for mass cytometry (#) and RNA sequencing (Δ) in COVID-19 patients (red) and controls (blue). The numbers in the Venn diagrams refer to respective patient and control cases in Table 1 and table S1. The table summarizes the total number of blood and biopsy samples allocated for mass cytometry and RNA sequencing.




**Fig. S2 Representative H&E staining of small intestinal biopsies of COVID-19 patients.**


Patient number in the top left corner corresponds with the patient number in table S4. All biopsies are duodenal with the exception of patient 12 which is from the terminal ileum. Scale bar; 100 $\mu$ m.




**Fig. S3 Representative immunofluorescence (IF) images of small intestinal biopsies of COVID-19 patients.** SARS-CoV-2 nucleocapsid (green), EPCAM (red) and DAPI (blue) in all COVID-19 patients where tissue was available for IF. Patient number in the top right corner corresponds with the patient number in table S4. All biopsies are duodenal with the exception of patient 12 which is from the terminal ileum. Patient 8 missing due to technical difficulties during IF staining. Scale bar; 100  $\mu$ m.




**Fig. S4 Representative immunofluorescence images of small intestinal biopsies of control patients.** SARS-CoV-2 nucleocapsid (green), EPCAM (red) and DAPI (blue) in duodenal biopsies (upper) and ileal biopsies (lower). Scale bar; 100  $\mu$ m.




**Fig. S5 Altered immune populations in the lamina propria of COVID-19 patients compared to controls.** (A) Relative frequencies of lamina propria immune cells in controls and COVID-19 patients. Open red circles denote patients with asymptomatic/mild/moderate disease while filled red circles denote patients with severe COVID-19. The bar plots show median frequencies. (B) The stacked bar graphs show the distribution of average frequencies of naïve and memory CD4+ and CD8+ T cells in the lamina propria of COVID-19 patients and controls.




**Fig. S6 Altered immune populations in the epithelial compartment (EC) of COVID-19 patients compared to controls.** (A) The heat map shows clustering and distribution of different cell types in the EC. Relative frequencies of (B) intraepithelial lymphocytes (IELs) and (C) plasma cells in the EC of controls and COVID-19 patients. Open red circles denote patients with asymptomatic/mild/moderate disease while filled red circles denote patients with severe COVID-19. The bar plots show median frequencies.



**Fig. S7 Altered immune populations in the blood of COVID-19 patients compared to controls.** (A) The heat map shows clustering and distribution of different immune cell types in the blood. Relative frequencies of (B) classical (dotted bars) and non-classical monocytes (open bars), (C) CD4+ regulatory T cells and (D) IgG+ plasma cells in the blood of controls and COVID-19 patients. Open red circles denote patients with asymptomatic/mild/moderate disease while filled red circles denote patients with severe COVID-19. The bar plots show median frequencies.




**Fig. S8 Altered T cell populations in blood and intestinal biopsies of COVID-19 patients compared to controls based on supervised analysis.** Representative CyTOF plots and bar plots comparing the frequencies of CD29+ CD38+ CD4+ and CD29+ CD38+ CD8+ T cells in (A) the blood and (B) lamina propria of controls (blue) and COVID-19 patients (red). Open red circles denote patients with asymptomatic/mild/moderate disease while filled red circles denote patients with severe COVID-19. The bar plots show median frequencies.



**Fig. S9 Distinct expression profiles in the intestinal epithelial compartment (EC) and lamina propria (LP).** **(A)** Principal Component Analysis (PCA) of EC and LP fractions of COVID-19 patients and controls. The two tissue fractions separate on the principal component 1 (x-axis). **(B)** Hierarchical clustering of average expression changes for 6636 genes (rows) characterizing the EC (red) or LP (blue) fractions (FDR  $\leq 0.05$ ) in the intestinal biopsies of COVID-19 patients and controls. The left panel indicates significant genes in yellow for each tissue compartment. The color bar (right panel) indicates the average log<sub>2</sub> fold-change (FC).

A


### GSEA: COVID-19 infected organoid models



Rank ordered genes: Inf EC vs control ( $\log FC^* - \log Pvalue$ )

B


### GSEA: Hallmark Pathways




Rank ordered genes: Inf EC vs control ( $\log FC^* - \log Pvalue$ )

**Fig. S10 Immune signatures in the epithelial compartment (EC) of COVID-19 patients.** Gene Set Enrichment Analysis (GSEA) was performed using a rank ordered list of genes differentially expressed in the infected EC vs control EC. The metric for ranking was  $\log FC^* - \log Pvalue$ . (A) GSEA was performed on the rank ordered EC gene set using SARS-CoV-2 infected organoid datasets. The gene sets tested were molecular signatures curated from SARS-CoV-2 infected


organoid experimental datasets using human small intestinal organoids (hSIOs) grown in either i) Wnt high expansion (EXP) medium (at adjP<0.05) or ii) differentiation (DIF) medium (at adjP<0.1). Only gene sets significantly enriched (at FDR <0.05) are displayed. **(B)** GSEA was performed for the same rank ordered EC gene set using the Hallmark Pathway datasets. Two significantly enriched pathways were found to be associated with upregulated genes in infected EC relative to controls (at FDR<0.05). Normalized enrichment score (NES) and FDR values are as indicated.




**Fig. S11 Flow diagram of the Discovery Cohort.** The diagram shows the total number of patients admitted to the Mount Sinai Health System between April 1-15, 2020 and the selection process that was adopted in order to select patients in the Discovery Cohort.



**Fig. S12 GI symptoms associated with reduced mortality and severity.** Kaplan-Meier curves for mortality stratified by (A) nausea and (B) vomiting for patients in the Discovery Cohort. P-values from log-rank test and 95% confidence intervals of Kaplan-Meier curves are shown. Below each Kaplan-Meier, the number of patients at risk for different time points are reported.



**Fig. S13 COVID-19 patients with GI symptoms have reduced levels of circulating IL-6 and IL-8. (A) IL-6, (B) IL-8, (C) TNF- $\alpha$  and (D) IL-1 $\beta$  at the time of admission in patients with and without GI symptoms.** Boxplots represent the median and interquartile range. P-values calculated using unpaired two-tailed t-test.



**Fig. S14 Correlation matrix (Pearson's) for 92 markers contained in the Olink platform. (A)**

Correlation matrix across patients with nausea (left panel) compared to patients without nausea (right panel); and **(B)** patients with vomiting (left panel) compared to patients without vomiting (right panel). Cluster assignment derived using unsupervised consensus clustering is reported on the top of the heatmap.

**Table S1.** Clinical characteristics of SARS-CoV-2 uninfected control patients who underwent endoscopic biopsies of the GI tract.

Control #	Age*	Sex	Days between negative NP SARS-CoV-2 swab and Procedure	Procedure	Tissue sample location
1	70-75	F	1	EGD	Duodenum
2	60-65	F	1	EGD	Duodenum
3	65-70	M	2	EGD & colonoscopy	Duodenum
4	40-45	M	1	EGD	Duodenum
5	65-70	M	1	EGD	Duodenum
6	70-75	M	1	EGD	Duodenum
7	65-70	F	1	EGD	Duodenum
8	70-75	F	2	EGD	Duodenum
9	50-55	M	1	EGD	Duodenum
10	75-80	F	1	Colonoscopy	Ileum

\* Age is provided as a range to obscure identifying information related to individuals

Abbreviations: EGD = Esophagogastroduodenoscopy, F = Female, M = Male

**Table S2.** Criteria for scoring disease severity in COVID-19 patients.

Severity Score	Criteria
Mild	SpO <sub>2</sub> >94% on room air AND no pneumonia on imaging
Moderate	SpO <sub>2</sub> <94% on room air OR pneumonia on imaging
Severe	High flow nasal cannula (HFNC), non-rebreather mask (NRBM), Bilevel Positive Airway Pressure (non-invasive positive airway ventilation), or Mechanical ventilation AND no pressor medications AND creatinine clearance > 30 AND ALT < 5x upper limit of normal
Severe with end organ damage (EOD)	High flow nasal cannula (HFNC), non-rebreather mask (NRBM), Bilevel Positive Airway Pressure (non-invasive positive airway ventilation), or Mechanical ventilation AND pressor medications OR creatinine clearance <30 OR new renal replacement therapy OR ALT > 5x upper limit of normal

**Table S3.** Clinical characteristics of COVID-19 patients including their symptoms on presentation, co-morbidities and treatment regimens.

Patient #	Clinical setting	Symptoms on presentation	Other symptoms / findings / complications	Highest level of oxygen required	COVID-19 Treatments
1	Inpatient -ICU	CVA	Pneumonia on imaging	Mechanical ventilation	HCQ and azithromycin
2	Inpatient -ICU	Fever, shortness of breath, vomiting and diarrhea		Room air	HCQ (given prior to admission at MSH) and steroids
3	Inpatient -non-ICU	Diarrhea and altered mental status	UTI, choledocholithiasis	Room air	Supportive care
4	Inpatient -ICU	Fever, cough, shortness of breath, abdominal pain	Cardiac arrest	Mechanical ventilation	HCQ, azithromycin, Remdesivir and therapeutic AC
5	Inpatient -non-ICU	Fever, nausea, vomiting and shortness of breath		HFNC	Steroids and therapeutic AC
6	Outpatient	Asymptomatic at time of procedure, tested for procedure	Subsequently developed CVA	Room air	Therapeutic AC
7	Inpatient -non-ICU	Asymptomatic at time of procedure, tested for procedure	Dysphagia	Room air	Supportive care
8	Inpatient -ICU	Shortness of breath, altered mental status	UTI, bacteremia	HFNC	HCQ, steroids, therapeutic AC
9	Inpatient -ICU	Shortness of breath		Mechanical ventilation	HCQ, azithromycin, steroids, therapeutic AC and convalescent plasma
10	NA	NA	NA	NA	NA
11	Inpatient -non-ICU	Shortness of breath, altered mental status	acute on chronic renal failure requiring HD	HFNC / BiPAP	HCQ, azithromycin, and steroids
12	Outpatient	Fatigue, myalgias, cough		Room air	Supportive care
13	Outpatient	Chills, fever	Epigastric pain radiating to back	Room air	Supportive care
14	Inpatient -ICU	Shortness of breath, generalized weakness		Mechanical ventilation	HCQ, azithromycin, steroids, therapeutic AC, convalescent plasma
15	Inpatient -non-ICU	Shortness of breath, abdominal pain		Room air	Supportive care
16	Outpatient	Myalgias	Obstructive jaundice	Room air	Supportive care
17	Outpatient	Asymptomatic at time of procedure, tested for procedure		Room air	Supportive care
18	Inpatient -non-ICU	Abdominal pain	Jaundice, UTI	Room air	Supportive care

Abbreviations: CVA = cerebrovascular accident, HCQ = hydroxychloroquine, UTI = urinary tract infection, HFNC = high flow nasal cannula.

**Table S4.** Histopathological characteristics of COVID-19 patients.

Patient #	Tissue used for IF	Viral protein detected by IF?	Increased IELs	Neutrophils	Other histopathologic abnormalities	Viral particles detected on EM?
2	Duodenum, ileum	yes (ileum and duodenum)	no	yes (ileum)	inflammation in ileum	not done
3	None available	N/A	yes (duodenum)	yes (mild, duodenum)	none	yes
4	Duodenum	yes	borderline	no	none	yes
5	None available	N/A	no	no	epithelial damage, villous blunting and reactive foveolar metaplasia	no
6	Duodenum	yes	no	yes	epithelial damage and foveolar metaplasia	no
7	Duodenum	yes	yes	yes (mild)	none	not done
8	None available	N/A	borderline	yes (mild)	none	no
9	Duodenum	yes	borderline	yes (mild)	epithelial damage	yes
11	None available	N/A	no	no	none	yes
12	Ileum	yes	no	no	none	yes
13	Duodenum	no	borderline	no	none	yes
15	Duodenum	yes	borderline	no	none	no
16	Duodenum	yes	no	no	none	no
17	Duodenum	yes	no	no	none	no
18	Duodenum	yes	patchy	yes (mild)	none	no

Histologic information in reference to tissue used for IF unless not available in which case inflammatory changes as documented in EM report.

**Table S5.** Histopathological characteristics of pre-pandemic controls.

Patient #	Age*	Sex	Tissue for IF	Reason for procedure	Medications
1	50-55	M	duodenum	epigastric pain	famotidine, ranitidine, azelastine-fluticasone, ipratropium bromide, levocetirizine, azelastine, omeprazole
2	65-70	F	duodenum and ileum	abdominal pain	none
3	80-85	F	duodenum	dysphagia	fluticasone-salmeterol, guaifenesin, albuterol, sennosides, Montelukast, losartan, amlodipine, acetaminophen, glipizide, atenolol, atorvastatin
4	75-80	F	duodenum	abdominal pain	losartan, aspirin, ferrous sulfate, metformin, omeprazole, pravastatin
5	75-80	F	duodenum	weight loss	spironolactone, apixaban, folic acid, torsemide, fluticasone
6	30-35	M	ileum	iron deficiency anemia	metformin, hydrochlorothiazide, enalapril
7	55-60	M	ileum	abdominal pain	divalproex, atorvastatin, benazepril, carvedilol, linagliptin, ondansetron, lamotrigine, lithium, rabeprazole, risperidone, alprazolam, oxycodone, glimepiride, allopurinol
8	40-45	M	ileum	rectal bleeding	none
9	50-55	F	ileum	CRC screening	acyclovir, acetaminophen
10	20-25	F	ileum	abdominal pain	none

Abbreviation: CRC, Colorectal Cancer

**Table S6.** Discovery Cohort basic demographics, clinical characteristics and outcomes. For age, the mean ± standard deviation is listed. For categorical variables, the number of patients followed by the percent of patients in parentheses is listed.

Discovery Cohort (n=634)	
Age (years)	64.0 ± 15.7
Male	369 (58.2)

**Race/ethnicities**

Hispanic	177 (27.9)
African-American	161 (25.4)
White	137 (21.6)
Asian	35 (5.5)
Other	124 (19.6)

**Comorbidities**

HTN	229 (36.1)
Diabetes mellitus	141 (22.2)
Obesity (BMI>30)*	211 (37.1)
Chronic lung disease	59 (9.3)
Heart disease	111 (17.5)
Chronic kidney disease	95 (15.0)
Cancer	66 (10.4)
HIV	11 (1.7)
IBD	7 (1.1)

**Disease severity**

Mild	54 (8.5)
Moderate	361 (56.9)
Severe	158 (24.9)
Severe with EOD	61 (9.6)

**Outcomes**

ICU admission	110 (17.4)
Mortality	151 (23.8)

**GI symptoms**

Nausea	157 (24.8)
Vomiting	82 (12.9)
Diarrhea	245 (38.6)
Any GI symptoms	299 (47.2)

\*BMI information available on 568/634 patients

**Table S7.** COVID-19 disease severity and mortality in patients with and without GI symptoms in the Discovery Cohort. Fisher's exact test used to calculate p-values.

GI symptom	Severity	GI symptom		p-value
		Presence (n)	Absence (n)	
Nausea	Mild	16	38	0.0112
	Moderate	102	259	
	Severe	32	126	
	Severe EOD	7	54	
Vomiting	Mild	10	44	0.0156
	Moderate	56	305	
	Severe	11	147	
	Severe EOD	5	56	
Diarrhea	Mild	26	28	0.0102
	Moderate	152	209	
	Severe	52	106	
	Severe EOD	15	46	
Any GI symptoms	Mild	31	23	0.0003
	Moderate	188	173	
	Severe	63	95	
	Severe EOD	17	44	

GI symptom	Mortality	GI symptom		p-value
		Presence (n)	Absence (n)	
Nausea	Non-survivor	21	130	0.0003
	Survivor	136	347	
Vomiting	Non-survivor	8	143	0.0008
	Survivor	74	409	
Diarrhea	Non-survivor	39	112	0.0002
	Survivor	206	277	
Any GI symptoms	Non-survivor	47	104	<0.0001
	Survivor	252	231	

**Table S8.** Basic demographics in survivors and non-survivors in the Discovery Cohort. For age, the mean  $\pm$  standard deviation and an unpaired two-tailed t-test was performed. For categorical variables, the number of patients followed by the percent of patients in parentheses is listed and the Fisher's exact test or the Chi-square test was used as appropriate.

	<b>Survivors (n=483)</b>	<b>Non-survivors (n=151)</b>	<b>p-value</b>
Age (years)	61.3 $\pm$ 15.2	72.6 $\pm$ 14.1	<0.0001
Male	287 (59.4)	82 (54.3)	0.30

**Disease severity**

Mild	48 (9.9)	6 (4.0)	<0.0001
Moderate	318 (65.8)	43 (28.5)	
Severe	95 (19.7)	63 (41.7)	
Severe with EOD	22 (4.6)	39 (25.8)	

**Table S9.** Confidence intervals of odds ratio based on 1000 bootstrap iterations for severity, mortality and ICU admission in the Discovery Cohort.

Severity	2.5%	50%	97.5%
(Intercept)	0.015	0.071	0.320
<b>Any GI Symptom</b>	0.378	0.559	0.844
baseline.GenderMale	0.939	1.380	2.090
baseline.Age	1.004	1.016	1.031
baseline.DIABETES	0.600	0.995	1.729
baseline.BMI	1.009	1.039	1.069
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN	0.293	0.503	0.876
baseline.RACE_ETHNICITY_HISPANIC	0.688	1.188	2.035
baseline.RACE_ETHNICITY_OTHER	0.771	1.286	2.245
baseline.HTN	0.636	0.990	1.543
baseline.Lung.Disease	0.272	0.562	1.063
baseline.Heart.Disease	0.673	1.095	1.842
	<b>2.5%</b>	<b>50%</b>	<b>97.5%</b>
(Intercept)	0.013	0.060	0.259
<b>Diarrhea</b>	0.433	0.653	0.978
baseline.GenderMale	0.963	1.413	2.124
baseline.Age	1.005	1.017	1.033
baseline.DIABETES	0.604	1.012	1.747
baseline.BMI	1.008	1.037	1.067
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN	0.300	0.521	0.920
baseline.RACE_ETHNICITY_HISPANIC	0.707	1.215	2.098
baseline.RACE_ETHNICITY_OTHER	0.777	1.311	2.280
baseline.HTN	0.634	0.977	1.529
baseline.Lung.Disease	0.267	0.546	1.042
baseline.Heart.Disease	0.686	1.113	1.826
	<b>2.5%</b>	<b>50%</b>	<b>97.5%</b>
(Intercept)	0.013	0.058	0.271
<b>Nausea</b>	0.329	0.563	0.880
baseline.GenderMale	0.932	1.364	2.089
baseline.Age	1.005	1.018	1.032
baseline.DIABETES	0.609	1.015	1.738
baseline.BMI	1.007	1.036	1.065
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN	0.322	0.543	0.946
baseline.RACE_ETHNICITY_HISPANIC	0.749	1.264	2.169
baseline.RACE_ETHNICITY_OTHER	0.816	1.340	2.338
baseline.HTN	0.615	0.950	1.477
baseline.Lung.Disease	0.248	0.516	0.980
baseline.Heart.Disease	0.676	1.091	1.830
	<b>2.5%</b>	<b>50%</b>	<b>97.5%</b>
(Intercept)	0.012	0.054	0.236
<b>Vomiting</b>	0.190	0.399	0.732
baseline.GenderMale	0.938	1.395	2.107
baseline.Age	1.006	1.018	1.032
baseline.DIABETES	0.615	1.032	1.744
baseline.BMI	1.006	1.036	1.065
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN	0.330	0.558	0.962
baseline.RACE_ETHNICITY_HISPANIC	0.766	1.286	2.191
baseline.RACE_ETHNICITY_OTHER	0.802	1.337	2.307
baseline.HTN	0.610	0.950	1.511
baseline.Lung.Disease	0.261	0.526	0.981
baseline.Heart.Disease	0.703	1.123	1.886

<b>Mortality</b>	<b>2.5%</b>	<b>50%</b>	<b>97.5%</b>
(Intercept)	0.000	0.003	0.022
<b>Any GI Symptom</b>	0.335	0.544	0.861
baseline.GenderMale	0.679	1.049	1.703
baseline.Age	1.036	1.053	1.074
baseline.DIABETES	0.527	0.930	1.605
baseline.BMI	1.010	1.043	1.081
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN	0.529	1.035	1.959
baseline.RACE_ETHNICITY_HISPANIC	0.867	1.597	2.899
baseline.RACE_ETHNICITY_OTHER	0.450	0.878	1.630
baseline.HTN	0.600	1.007	1.665
baseline.Lung.Disease	0.342	0.778	1.577
baseline.Heart.Disease	0.652	1.154	2.028
	<b>2.5%</b>	<b>50%</b>	<b>97.5%</b>
(Intercept)	0.000	0.003	0.017
<b>Diarrhea</b>	0.388	0.638	0.985
baseline.GenderMale	0.702	1.076	1.737
baseline.Age	1.038	1.055	1.076
baseline.DIABETES	0.531	0.945	1.608
baseline.BMI	1.007	1.041	1.079
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN	0.562	1.071	2.020
baseline.RACE_ETHNICITY_HISPANIC	0.901	1.640	2.898
baseline.RACE_ETHNICITY_OTHER	0.468	0.900	1.709
baseline.HTN	0.595	1.001	1.665
baseline.Lung.Disease	0.333	0.752	1.561
baseline.Heart.Disease	0.660	1.166	2.020
	<b>2.5%</b>	<b>50%</b>	<b>97.5%</b>
(Intercept)	0.000	0.003	0.019
Nausea	0.255	0.490	0.886
baseline.GenderMale	0.669	1.041	1.719
baseline.Age	1.038	1.055	1.075
baseline.DIABETES	0.528	0.938	1.623
baseline.BMI	1.006	1.040	1.077
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN	0.591	1.112	2.116
baseline.RACE_ETHNICITY_HISPANIC	0.956	1.718	3.085
baseline.RACE_ETHNICITY_OTHER	0.474	0.916	1.703
baseline.HTN	0.579	0.960	1.571
baseline.Lung.Disease	0.313	0.699	1.457
baseline.Heart.Disease	0.655	1.155	2.007
	<b>2.5%</b>	<b>50%</b>	<b>97.5%</b>
(Intercept)	0.000	0.002	0.016
<b>Vomiting</b>	0.116	0.364	0.753
baseline.GenderMale	0.690	1.070	1.759
baseline.Age	1.038	1.055	1.076
baseline.DIABETES	0.558	0.970	1.652
baseline.BMI	1.006	1.040	1.077
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN	0.609	1.145	2.144
baseline.RACE_ETHNICITY_HISPANIC	1.004	1.746	3.086
baseline.RACE_ETHNICITY_OTHER	0.463	0.907	1.697
baseline.HTN	0.586	0.974	1.620
baseline.Lung.Disease	0.318	0.717	1.489
baseline.Heart.Disease	0.670	1.186	2.025

<b>ICU admission</b>	<b>2.5%</b>	<b>50%</b>	<b>97.5%</b>
(Intercept)	0.03	0.17	1.11
<b>Any GI Symptom</b>	0.46	0.75	1.19
baseline.GenderMale	1.23	2.00	3.26
baseline.Age	0.98	0.99	1.01
baseline.DIABETES	0.91	1.70	3.23
baseline.BMI	0.98	1.02	1.05
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN	0.26	0.57	1.20
baseline.RACE_ETHNICITY_HISPANIC	0.79	1.50	2.95
baseline.RACE_ETHNICITY_OTHER	0.48	0.98	1.99
baseline.HTN	0.34	0.61	1.08
baseline.Lung.Disease	0.15	0.63	1.45
baseline.Heart.Disease	0.20	0.51	0.97
	<b>2.5%</b>	<b>50%</b>	<b>97.5%</b>
(Intercept)	0.02	0.16	1.10
<b>Diarrhea</b>	0.45	0.76	1.25
baseline.GenderMale	1.23	2.00	3.27
baseline.Age	0.98	0.99	1.01
baseline.DIABETES	0.89	1.70	3.25
baseline.BMI	0.98	1.02	1.05
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN	0.26	0.56	1.19
baseline.RACE_ETHNICITY_HISPANIC	0.78	1.50	2.96
baseline.RACE_ETHNICITY_OTHER	0.48	0.98	1.98
baseline.HTN	0.34	0.61	1.09
baseline.Lung.Disease	0.15	0.62	1.44
baseline.Heart.Disease	0.20	0.52	0.99
	<b>2.5%</b>	<b>50%</b>	<b>97.5%</b>
(Intercept)	0.02	0.14	0.95
<b>Nausea</b>	0.45	0.85	1.42
baseline.GenderMale	1.24	2.00	3.33
baseline.Age	0.98	0.99	1.01
baseline.DIABETES	0.91	1.74	3.31
baseline.BMI	0.98	1.02	1.05
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN	0.27	0.60	1.25
baseline.RACE_ETHNICITY_HISPANIC	0.81	1.54	3.00
baseline.RACE_ETHNICITY_OTHER	0.49	0.99	1.97
baseline.HTN	0.33	0.59	1.06
baseline.Lung.Disease	0.14	0.60	1.40
baseline.Heart.Disease	0.20	0.51	0.98
	<b>2.5%</b>	<b>50%</b>	<b>97.5%</b>
(Intercept)	0.02	0.15	0.98
<b>Vomiting</b>	0.16	0.53	1.08
baseline.GenderMale	1.21	1.98	3.26
baseline.Age	0.98	0.99	1.01
baseline.DIABETES	0.92	1.74	3.31
baseline.BMI	0.98	1.02	1.05
baseline.RACE_ETHNICITY_BLACK OR AFRICAN-AMERICAN	0.27	0.60	1.26
baseline.RACE_ETHNICITY_HISPANIC	0.82	1.55	3.01
baseline.RACE_ETHNICITY_OTHER	0.48	0.99	1.96
baseline.HTN	0.34	0.61	1.07
baseline.Lung.Disease	0.15	0.62	1.43
baseline.Heart.Disease	0.20	0.52	0.99

**Table S10.** Age, gender and mortality in an External Validation (Italian) Cohort stratified by presence or absence of diarrhea on admission. For age, the mean ± standard deviation and an unpaired two tailed t-test was performed. For categorical variables, the number of patients followed by the percent of patients in parentheses is listed and the Fisher's exact test or the Chi-square test was used as appropriate.

	<b>Diarrhea on admission (n=80)</b>	<b>No diarrhea on admission (n=207)</b>	<b>p-value</b>
Age (years)	60.6 ± 13.9	65.5 ± 13.3	<b>0.006</b>
Male	46 (57.5)	149 (72.0)	<b>0.024</b>
ICU admission	9 (11.3)	43 (20.8)	0.06
Mortality	8 (10.0)	49 (23.7)	<b>0.008</b>
Death or ICU admission	16 (20.0)	83 (40.1)	<b>0.001</b>

**Table S11.** Confidence interval of AUC (95%) based on 1000 bootstrap iterations for severity, mortality and ICU admission in the Internal Validation Cohort.

<b>Severity</b>	<b>2.50%</b>	<b>50%</b>	<b>97.50%</b>
Age + BMI	0.539	0.587	0.598
Age + BMI + Nausea	0.567	0.608	0.619
Age + BMI + Vomiting	0.558	0.607	0.618
Age + BMI + Diarrhea	0.574	0.630	0.651
Age + BMI + Any GI symptoms	0.605	0.640	0.651

<b>Mortality</b>	<b>2.50%</b>	<b>50%</b>	<b>97.50%</b>
Age + BMI	0.685	0.700	0.702
Age + BMI + Nausea	0.698	0.717	0.722
Age + BMI + Vomiting	0.702	0.719	0.724
Age + BMI + Diarrhea	0.697	0.718	0.726
Age + BMI + Any GI symptoms	0.708	0.727	0.736

<b>ICU admission</b>	<b>2.50%</b>	<b>50%</b>	<b>97.50%</b>
Age + BMI	0.534	0.560	0.599
Age + BMI + Nausea	0.496	0.523	0.650
Age + BMI + Vomiting	0.488	0.515	0.626
Age + BMI + Diarrhea	0.562	0.649	0.667
Age + BMI + Any GI symptoms	0.570	0.647	0.670

**Table S12.** IL-6, IL-8, TNF- $\alpha$ , and IL-1 $\beta$  concentrations on admission in patients with and without GI symptoms. Benjamini adjusted p-values (signed - log10 scale) from t-test are reported. Association passing a 10% FDR are highlighted in yellow.

	<b>Nausea</b>	<b>Vomiting</b>	<b>Diarrhea</b>	<b>Any GI Symptoms</b>
IL-6	-1.958	-0.473	-2.226	-2.484
IL-8	-4.098	-1.440	-2.302	-3.133
TNF- $\alpha$	-0.815	-0.311	-0.406	-0.864
IL-1 $\beta$	-0.295	-0.473	-0.295	-0.295

**Table S13.** Cluster assignment for each of the 92 Olink analytes.

Marker	Cluster
IL8	1
AXIN1	1
OSM	1
CCL4	1
TGF.alpha	1
TNFSF14	1
HGF	1
SIRT2	1
EN.RAGE	1
CASP.8	1
TWEAK	1
STAMBP	1
VEGFA	2
CDCP1	2
IL.17C	2
CXCL9	2
CST5	2
FGF.23	2
FGF.5	2
LIF.R	2
FGF.21	2
IL.15RA	2
IL.10RB	2
PD.L1	2
MMP.10	2
TNF	2
CD5	2
X4E.BP1	2
CD40	2
CCL25	2
CX3CL1	2
TNFRSF9	2
CSF.1	2
CD8A	3
CD244	3
TRAIL	3
CD6	3
SCF	3
CCL11	3
CCL19	3
TRANCE	3
IL.12B	3
CCL3	3
Flt3L	3
DNER	3
IFN.gamma	3
FGF.19	3
MCP.2	3
TNFB	3

Marker	Cluster
MCP.3	4
OPG	4
uPA	4
IL6	4
MCP.1	4
IL18	4
IL.18R1	4
IL10	4
CCL23	4
CXCL10	4
LIF	4
CCL20	4
ADA	4
GDNF	5
IL.17A	5
IL.20RA	5
IL.2RB	5
IL.1.alpha	5
IL2	5
TSLP	5
SLAMF1	5
IL.10RA	5
IL.22.RA1	5
Beta.NGF	5
IL.24	5
IL13	5
ARTN	5
IL.20	5
CCL28	5
IL33	5
IL4	5
NRTN	5
NT.3	5
IL5	5
IL7	6
LAP.TGF.beta.1	6
CXCL11	6
CXCL1	6
MCP.4	6
MMP.1	6
CXCL5	6
CXCL6	6
ST1A1	6

**Table S14.** Olink analytes in patients with and without GI symptoms. P-values from t-test comparing patients with and without GI symptoms. Signed Benjamini-Hochberg adjusted p-value (-log10 scale) are reported.

	<b>Any GI Symptoms</b>	<b>Nausea</b>	<b>Vomiting</b>	<b>Diarrhea</b>
IL8	-1.315	-0.654	-1.345	-1.562
VEGFA	0.006	0.014	-0.356	-0.027
CD8A	-0.823	-0.175	0.193	-0.823
MCP.3	-0.524	-1.437	-0.422	-0.254
GDNF	-1.355	-1.345	-0.014	-1.490
CDCP1	-0.449	-0.309	-0.175	-0.524
CD244	-0.023	0.110	0.126	-0.017
IL7	1.345	0.175	-0.123	1.345
OPG	-2.183	-1.209	-0.014	-2.183
LAP.TGF.beta.1	0.356	-0.006	-0.626	0.407
uPA	-0.156	-0.009	0.126	-0.385
IL6	-1.063	-1.022	-0.254	-0.747
IL.17C	-1.209	-0.287	-0.023	-1.455
MCP.1	-0.175	-0.654	-0.458	-0.187
IL.17A	-2.183	-1.097	-1.419	-2.183
CXCL11	0.058	-0.195	-0.004	0.027
AXIN1	-0.009	-0.031	-1.209	-0.026
TRAIL	1.063	0.626	0.314	0.458
IL.20RA	-0.548	-0.573	-0.563	-0.618
CXCL9	-0.573	-0.367	0.023	-1.209
CST5	-0.626	-0.187	-0.004	-0.969
IL.2RB	-0.156	-0.028	0.009	-0.044
IL.1.alpha	0.046	-0.023	0.001	0.162
OSM	-0.178	-0.117	-0.175	-0.242
IL2	-0.341	-0.424	-0.287	-0.264
CXCL1	-0.058	-0.533	-0.733	-0.164
TSLP	0.009	0.001	-0.031	-0.009
CCL4	-0.287	-0.022	0.022	-1.355
CD6	-0.001	0.027	0.363	0.001
SCF	-0.245	-0.022	-0.114	-0.082
IL18	-0.254	-0.068	0.332	-0.434
SLAMF1	-0.618	-0.707	-0.190	-0.708
TGF.alpha	-1.087	-0.626	-0.675	-1.345
MCP.4	0.191	-0.175	-0.461	0.058
CCL11	-0.327	-0.440	-1.209	-0.260
TNFSF14	0.014	-0.014	-0.434	-0.012
FGF.23	-0.556	-0.058	0.036	-1.209
IL.10RA	0.027	0.218	-0.044	-0.026
FGF.5	-0.823	-0.164	-0.027	-1.365
MMP.1	0.110	0.156	-0.218	0.027
LIF.R	-0.347	-0.009	0.310	-0.358
FGF.21	-0.495	-0.003	0.056	-0.880
CCL19	-0.044	-0.227	-0.156	-0.175
IL.15RA	-1.345	-0.175	0.022	-2.177
IL.10RB	-1.355	-0.389	-0.079	-2.183
IL.22.RA1	-0.073	-0.022	-0.009	-0.254
IL.18R1	-0.208	-0.054	0.175	-0.156
PD.L1	-0.441	-0.195	0.031	-0.702

Beta.NGF	-0.573	-0.458	-0.022	-0.495
CXCL5	-0.014	-0.144	-0.424	-0.042
TRANCE	0.933	0.458	0.236	0.654
HGF	-0.626	-0.333	-0.009	-0.529
IL.12B	0.060	0.058	-0.009	0.038
IL.24	-0.536	-0.218	0.023	-0.618
IL13	-0.007	0.075	0.068	-0.126
ARTN	-1.209	-1.365	-0.618	-1.345
MMP.10	-1.562	-0.967	-0.156	-2.073
IL10	-0.379	-0.377	0.058	-0.270
TNF	-0.643	-0.175	-0.027	-0.932
CCL23	-0.023	-0.218	0.001	0.001
CD5	-0.823	-0.357	-0.036	-0.933
CCL3	-0.933	-0.553	-0.576	-1.490
Flt3L	0.031	-0.009	-0.377	-0.009
CXCL6	-0.156	-0.385	-0.347	-0.385
CXCL10	-0.001	-0.441	-0.012	0.031
X4E.BP1	-0.733	-0.211	0.064	-1.223
IL.20	-0.247	-1.022	-0.270	-0.195
SIRT2	-0.123	-0.164	-0.332	-0.162
CCL28	-2.183	-2.183	-0.737	-2.183
DNER	0.175	0.317	0.332	0.202
EN.RAGE	-0.357	-0.193	-0.166	-0.526
CD40	-0.823	-0.079	0.001	-1.490
IL33	-0.236	-0.164	0.023	-0.287
IFN.gamma	0.218	0.044	0.175	0.270
FGF.19	-0.458	-0.001	-0.036	-1.355
IL4	-0.020	-0.175	-0.027	-0.009
LIF	-1.345	-0.526	-0.573	-1.355
NRTN	0.001	-0.168	-0.036	-0.012
MCP.2	0.319	-0.327	-0.036	1.231
CASP.8	-0.438	-0.377	-0.264	-0.731
CCL25	-0.264	0.025	-0.075	-0.626
CX3CL1	-0.556	-0.164	-0.009	-0.810
TNFRSF9	-1.345	-0.175	-0.012	-2.029
NT.3	-0.012	-0.363	0.009	-0.122
TWEAK	-0.014	0.014	-0.113	-0.012
CCL20	-0.737	-0.576	0.187	-0.823
ST1A1	0.156	-0.025	-0.175	0.068
STAMBPs	-0.201	-0.171	-0.175	-0.377
IL5	0.156	-0.009	0.156	-0.009
ADA	-0.259	-0.270	0.175	-0.434
TNFB	0.009	-0.009	-0.036	0.014
CSF.1	-0.458	-0.028	0.012	-0.450

**Table S15.** List of antibodies used for microscopy studies.

Antigen	Clone	Vendor	Catalogue number	Host	Conjugation	Dilution
ACE2	Polyclonal	Abcam	ab15348	rabbit	Unconjugated	1:1000
EPCAM	SPM491	GeneTex	GTX34693	mouse	Unconjugated	1:100
SARS-CoV-2 nucleocapsid	Polyclonal	N/A*	N/A	rabbit	Unconjugated	1:2000
No known specificity (isotype control)	Polyclonal	Abcam	ab37415	rabbit	Unconjugated	variable
Yeast GAL4 (isotype control)	15-6E10A7	Abcam	ab170190	mouse	Unconjugated	variable
Mouse IgG H&L	Polyclonal	Abcam	ab150116	goat	Alexa Fluor 594	1:1000
Rabbit IgG H&L	Polyclonal	Abcam	ab150077	goat	Alexa Fluor 488	1:1000